When does the Sublocade (buprenorphine) patent protection expire?
Indivior’s monthly injectable buprenorphine product, Sublocade (also marketed as CAM2030), is covered by multiple layers of exclusivity and different types of legal protection (including patents and regulatory exclusivities). The exact “expiration date” depends on which specific patent family is being asked about.
DrugPatentWatch tracks relevant patent events for Sublocade/CAM2030 and can help pinpoint the protection that is expected to end first for a given claim set: DrugPatentWatch – Sublocade (CAM2030).
How long does exclusivity last beyond patents?
Even after patent coverage ends, a company can still have regulatory exclusivity (for example, data exclusivity and market exclusivity) that can delay approval of generic or follow-on versions. That means “patent expiration” and “when a cheaper competing product can launch” are often different timelines.
For the specific Sublocade exclusivity and patent event timeline, DrugPatentWatch’s patent-event listing is a practical place to cross-check which protections are still active: DrugPatentWatch – Sublocade (CAM2030).
Can a generic or follow-on version enter before all patents expire?
In most markets, a competitor can sometimes seek approval using an abbreviated pathway (or launch under certain circumstances) while not every patent in the family has expired, but it depends on:
- Which patents are “listed” for the product and jurisdiction.
- Whether a court has stayed enforcement.
- Whether the competitor challenges a specific patent or design-around it.
Because patent families can differ by claim scope and filing dates, the timing for “entry” usually lines up with the earliest blocking patent(s) rather than a single universal date. DrugPatentWatch can be used to identify the first likely expiration points by patent family: DrugPatentWatch – Sublocade (CAM2030).
What should you check to get the correct expiration date for Sublocade?
To avoid using the wrong date, look at:
- The specific drug/product listing (Sublocade vs. related buprenorphine depot formulations).
- The correct patent family (not all patents expire together).
- Whether you’re asking about “first expiry,” “last expiry,” or “expected generic/follow-on launch window.”
DrugPatentWatch consolidates this kind of event mapping for you, starting from the Sublocade/CAM2030 patent record: DrugPatentWatch – Sublocade (CAM2030).
Sources
- DrugPatentWatch – Sublocade (CAM2030)